Statement: the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments.
Primary_evidence: Outcome Measurement:    Central Nervous System (CNS) Objective Response Rate   CNS objective response rate is the percentage of participants that achieve CNS complete or partial response as follows:   CNS complete response (CR) is achieved if all of the following are satisfied:   Complete resolution of all measurable (>= 1 cm in longest dimension [LD]) and non-measurable brain metastases   No new CNS lesions (defined as any new lesion >= 6 mm in LD)   Stable or decreasing steroid dose   No new/progressive tumor-related neurologic signs or symptoms   No progression of extra-CNS disease as assessed by RECIST   CNS partial response (PR) is achieved if all of the following are satisfied:   ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline   No progression on non-measurable lesions   No new CNS lesions (defined as any new lesion >/= 6 mm in LD)   Stable or decreasing steroid dose   No new/progressive tumor-related neurologic signs or symptoms   No progression of extra-CNS disease as assessed by RECIST   Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. Results 1:    Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+)   Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.   carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle   bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle   trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only   *8mg/kg loading dose in cycle 1 for some participants   HER-2: human epidermal growth factor receptor 2   Overall Number of Participants Analyzed: 38   Measure Type: Number   Unit of Measure: percentage of participants  63        (47 to 77)
Secondary_evidence: Outcome Measurement:    Objective Response Rate (ORR)   Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.   Time frame: Up to 2 years. Results 1:    Arm/Group Title: NKTR-102 14 Day   Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: percentage of subjects  28.6        (14.6 to 46.3) Results 2:    Arm/Group Title: NKTR-102 21 Days   Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: percentage of subjects  35        (14.6 to 46.3)